Hyun Bae
Fortune : 15 256 $ au 31/07/2026
Fortune : 15 256 $ au 31/07/2026
Dr. Hyun W.
Bae, MD, is an Independent Director at Kairos Pharma Ltd. and a Professor-Orthopaedic Surgery at Cedars-Sinai Medical Center.
He is on the Board of Directors at Kairos Pharma Ltd. Dr. Bae was previously employed as a Chief Medical Officer & Director by Prosidyan, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from Yale University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KAIROS PHARMA, LTD. 0,23% | 31/03/2026 | 49 855 ( 0,23% ) | 15 256 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| KAIS PHARPAR | Directeur/Membre du Conseil | 09/09/2020 |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Corporate Officer/Principal | - |
| Sociétés | Poste | Fin |
|---|---|---|
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Process Industries |
Kairos Pharma Ltd.
Kairos Pharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national